RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models

Investigators Present Data Supporting Disease-Modifying Potential of the Io Therapeutics RXR Agonist Compound IRX4204 in Parkinson’s Disease SPRING, Texas, Aug. 05, 2026 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas, announced today the presentation of new research demonstrating that IRX4204, the company’s phase II clinical stage highly selective […]